) fourth quarter 2012 loss of 56 cents per share was wider than
the Zacks Consensus Estimate of a loss of 44 cents per share and
the year-ago loss of 14 cents per share. The wider loss was due
to higher operating expenses.
The company's net product revenue for the fourth quarter of
2012 came in at $2.0 million. The company did not record any
revenues during the prior-year quarter. The Zacks Consensus
Estimate stood at $4 million for the fourth quarter 2012.
For full year 2012, Vivus reported a loss of $1.42 per share,
wider than the year-ago loss of 56 cents and the Zacks Consensus
Estimate of a loss of $1.30 per share.
The company's portfolio comprises two approved products: Qsymia
and Stendra (avanafil). Qsymia was approved by the US Food and
Drug Administration (FDA) in July 2012.
The FDA cleared Qsymia as an adjunct to a healthy diet (low on
calories) and increased physical activity for chronic weight
management in obese (Body Mass Index, or BMI - 30 or more) or
overweight (BMI - 27 or more) adults suffering from at least one
weight-related co-morbid condition. However, the CHMP had
rendered a negative opinion on the marketing authorization
application (MAA) for Qsymia.
ARENA PHARMA (ARNA): Free Stock Analysis
CYTOKINETCS INC (CYTK): Free Stock Analysis
OREXIGEN THERAP (OREX): Free Stock Analysis
VIVUS INC (VVUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Stendra was approved by the FDA in Apr 2012 for erectile
dysfunction. The drug is under review in the EU WITH A decision
from the European Medicines Agency (EMA) expected in the second
quarter of 2013.
In the fourth quarter of 2012 research and development expenses
were $7.8 million, up 45% year over year. Selling, general and
administrative expenses shot up 670% to $50.3 million due to
increased expenditure related to the commercialization of Qsymia.
We remind investors that apart from Qsymia, another weight-loss
Arena Pharmaceuticals, Inc.'s
) Belviq, also received approval in the US last year. O
rexigen Therapeutics, Inc.
) is also developing a candidate, Contrave, targeting the
lucrative obesity market.
Vivus, a biopharmaceutical company, currently carries a Zacks
Rank #3 (Hold). Biopharma companies that currently look more
) with a Zacks Rank #1 (Strong Buy).